Lab-Grown Blood: A Potential Solution to Global Shortages?

The world's blood supply is facing increasing strain, with shortages impacting healthcare systems globally. Millions die each year due to lack of access to blood. Scientists are racing to develop lab-grown and synthetic blood alternatives to address this critical need, with recent clinical trials showing promising results. While challenges remain in scaling production and reducing costs, lab-made blood could revolutionize transfusion medicine, particularly for those with rare blood types and in emergency situations.

The Growing Need for Blood Alternatives

The demand for blood transfusions is constant and widespread, supporting surgeries, trauma care, cancer treatment, and management of genetic bleeding disorders. The American Red Cross estimates that about 29,000 units of red blood cells are needed each day in the U.S. However, the current blood donation system faces several limitations. Blood donations have declined, particularly among younger people, and have not recovered to pre-pandemic levels. Blood has a limited shelf life: whole blood lasts 21-35 days, red blood cells up to 42 days, and platelets only about five days. External factors such as holidays, extreme weather, wars, and pandemics can disrupt donations. These shortages are especially acute in low- and middle-income countries, creating "blood deserts" where more than 75% of patients needing transfusions cannot access blood.

Two Paths to Artificial Blood: Lab-Grown vs. Synthetic

Researchers are exploring two main approaches to creating blood alternatives: lab-grown blood and synthetic blood. Lab-grown blood involves growing human red blood cells in a controlled environment outside the body. Scientists use hematopoietic stem cells, which can turn into any kind of blood cell, and coax them into becoming red blood cells. This method could make the treatment of certain medical cases more effective. For example, lab-grown platelets may be better at stopping bleeding in trauma patients compared to those given to leukemia patients.

Synthetic blood, on the other hand, is a completely man-made substitute that does not contain human cells. These engineered molecules mimic the function of blood cells by transporting oxygen. Synthetic blood is designed mainly for emergency use or military medicine, where immediate oxygen delivery is needed but matching blood types is difficult. The United States military has invested $46 million in developing ErythroMer, a synthetic blood substitute designed to be universally compatible and stable without refrigeration.

Clinical Trials and Progress

Clinical trials are underway to test the safety and efficacy of both lab-grown and synthetic blood products. In 2022, a clinical trial in the UK marked a milestone by transfusing laboratory-grown red blood cells into human volunteers to assess their safety and longevity. A small initial study in Japan in 2022 tested hemoglobin vesicles, tiny artificial blood components designed to carry oxygen, in healthy male volunteers. Some participants experienced mild side effects, such as fever and rash, but these issues resolved quickly.

Japan is aiming to be the first country to deploy artificial blood for real-world medical care, with clinical trials involving healthy adults beginning by March 2025. The trial will start by administering 100 to 400 milliliters of the artificial blood to volunteers. If no side effects occur, researchers will move on to broader studies. The artificial blood can be stored for up to two years at room temperature, a dramatic improvement over the shelf life of donated blood.

Overcoming Challenges and Scaling Up

Despite the progress, significant challenges remain before lab-grown or synthetic blood can become widely available. One of the biggest hurdles is scaling up production to meet clinical demand. Producing lab-grown blood is currently much more expensive than using donated blood. In 2013, the Defense Advanced Research Projects Agency (DARPA) reported that the chemical materials required to produce one unit of lab-grown blood cost more than $90,000. Through advances in production methods, this cost has been reduced to less than $5,000 per unit. By comparison, hospitals in the U.S. paid an average of $215 per unit of donated red blood cells in 2019.

Another challenge is ensuring the safety and functionality of lab-grown or synthetic blood products. Regulators like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency are still determining whether lab-grown blood should be classified as cell therapy or medicine, which would determine how it would be regulated.

Ethical Considerations and Future Implications

As lab-grown and synthetic blood technologies advance, ethical considerations must be addressed. Some argue that it is unethical to offer patients synthetic alternatives when donor blood is proven to work well. However, in situations where donor blood is not an option, such as on a remote battlefield, synthetic blood products may be more effective than nothing. Ensuring equitable access to these potentially life-saving technologies is also crucial.

Despite the challenges, the potential benefits of lab-grown and synthetic blood are enormous. These alternatives could address blood shortages, particularly for those with rare blood types. They could also be invaluable in crisis situations, such as pandemics, wars, or natural disasters, when there is a sudden surge in demand. Moreover, artificial blood could be used to treat members of religious groups, like Jehovah's Witnesses, who refuse regular blood transfusions on religious grounds.

A Promising Future for Blood Alternatives

The development of lab-grown and synthetic blood is a complex and challenging endeavor, but one with the potential to revolutionize healthcare. While widespread use may still be several years away, the progress made in recent years is encouraging. With ongoing research, technological advancements, and careful consideration of ethical implications, lab-made blood could play a vital role in addressing global blood shortages and saving countless lives.